Literature DB >> 19708091

Required length of follow-up after transanal advancement flap repair of high transsphincteric fistulas.

L E Mitalas1, M P Gosselink, D M J Oom, D D E Zimmerman, W R Schouten.   

Abstract

OBJECTIVE: Repair of high perianal fistulas presents a major surgical challenge. Transanal advancement flap repair (TAFR) provides a useful tool in the treatment of these fistulas. Initially promising results have been reported. More recent studies indicate that TAFR fails in one out of three patients. The aim of the present study was to determine the appropriate length of follow-up needed to assess the healing rate after TAFR of high transsphincteric fistulas.
METHOD: Between 1992 and 2000 a consecutive series of 80 patients with a high transsphincteric fistula of cryptoglandular origin underwent TAFR. Medical records of all patients were studied. The initial healing rate and the median healing time were assessed. The initial outcome was successful in 54 patients. The medical records revealed that only one of these patients presented with a recurrent fistula after 28 months. The other 53 patients were sent a questionnaire in 2006 aimed to determine whether they had any complaints or signs of a recurrent fistula.
RESULTS: The initial healing rate was 68%. The median healing time was 3.6 months. The completed questionnaire was returned by 48 patients. None of these patients reported any complaints or signs of a recurrent fistula. Median duration of follow-up in these patients was 92 months.
CONCLUSION: At a median time interval of 3.6 months fistula healing was observed in 54 patients (68%). Only one patient (2%) encountered a recurrence. The length of follow-up can be restricted to the healing time.

Entities:  

Mesh:

Year:  2009        PMID: 19708091     DOI: 10.1111/j.1463-1318.2008.01666.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

Review 1.  Complex anal fistula remains a challenge for colorectal surgeon.

Authors:  F Cadeddu; F Salis; G Lisi; I Ciangola; G Milito
Journal:  Int J Colorectal Dis       Date:  2015-01-09       Impact factor: 2.571

2.  Ligation of Intersphincteric Fistula Tract: a Sphincter-Sparing Option for Complex Fistula-in-Ano.

Authors:  Erin O Lange; Linda Ferrari; Mukta Krane; Alessandro Fichera
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

3.  Cryptoglandular anal fistulas.

Authors:  Andreas Ommer; Alexander Herold; Eugen Berg; Alois Fürst; Marco Sailer; Thomas Schiedeck
Journal:  Dtsch Arztebl Int       Date:  2011-10-21       Impact factor: 5.594

4.  Fistulectomy and endorectal advancement flap repair for cryptoglandular anal fistula: recurrence and functional outcome over 10 years of follow-up.

Authors:  Carlos Chaveli Diaz; Irene Esquiroz Lizaur; José Marzo Virto; Fabiola Oteiza Martínez; Gregorio Gonzalez Álvarez; Mario de Miguel Velasco; Miguel Ángel Ciga Lozano
Journal:  Int J Colorectal Dis       Date:  2021-02-12       Impact factor: 2.571

5.  Identification of epithelialization in high transsphincteric fistulas.

Authors:  L E Mitalas; R S van Onkelen; K Monkhorst; D D Zimmerman; M P Gosselink; W R Schouten
Journal:  Tech Coloproctol       Date:  2012-01-10       Impact factor: 3.781

6.  Surgery for fistula-in-ano in a specialist colorectal unit: a critical appraisal.

Authors:  Pierpaolo Sileri; Federica Cadeddu; Stefano D'Ugo; Luana Franceschilli; Giovanna Del Vecchio Blanco; Elisabetta De Luca; Emma Calabrese; Sara Mara Capperucci; Valeria Fiaschetti; Giovanni Milito; Achille Lucio Gaspari
Journal:  BMC Gastroenterol       Date:  2011-11-09       Impact factor: 3.067

7.  Efficacy and safety of autologous adipose-derived stromal vascular fraction enriched with platelet-rich plasma in flap repair of transsphincteric cryptoglandular fistulas.

Authors:  W R Schouten; J H C Arkenbosch; C J van der Woude; A C de Vries; H P Stevens; G M Fuhler; R S Dwarkasing; O van Ruler; E J R de Graaf
Journal:  Tech Coloproctol       Date:  2021-10-04       Impact factor: 3.781

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.